Axsome Therapeutics Inc (AXSM)

[Nelson2]

LOL mate. Good stuff

GLTA

[georgejjl]

BARCHART OPINION for AXSM

https://www.barchart.com/stocks/quotes/AXSM/opinion

Good luck and GOD bless,

[HANUMAN]

Just the thought of $10 a pill is depressing. Will it cure that?

[georgejjl]

Possible SHORT SQUEEZE for AXSM stock NEXT WEEK!!!

A short squeeze is an unusual condition that triggers rapidly rising prices in a stock or other tradable security. For a short squeeze to occur, the security must have an unusual degree of short sellers holding positions in it. The short squeeze begins when the price jumps higher unexpectedly. The condition plays out as a significant measure of the short sellers coincidentally decide to cut losses and exit their positions.

Good luck and GOD bless,

[Nelson2]

See you at the cashier’s window!

GLTU

[georgejjl]

There are over 20 million people in the USA alone who have been diagnosed with major depressive disorder. The recommended dosing for Auvelity (dextromethorphan-bupropion (45 mg/105 mg tablet) is once daily for the first 3 days and twice daily thereafter for as long as prescribed by the physician.

Assuming initially just 10% of the 20 million are treated, that would be 2 million people taking Auvelity 2 times per day that would be 4 million tablets (capsules) of Auvelity per day for the US alone. if we assume that the cost is say $10 per tablet (capsule), then that would be $40 million per day in revenue for Axsome in the USA alone. With an average of 365.25 days per year.

Correct me if I am wrong but that appears to be about $14.6 BILLION in revenue for the US alone with just a 10% market penetration and a cost of just $10 per pill.

Good luck and GOD bless,

[Nelson2]

I am an investor as well. Of the many stocks I own there is, on seldom occasion, one has a huge acceleration in price. Like to pocket some profits in those scenarios.
To each their own

GLTU

[georgejjl]

I am an investor rather than a trader so I don't really have a target price at which to sell next week. I read recently that based on the Axsome pipeline they believe that AXSM should have a FMV (Fair Market Value) of greater than $400.00 per share.

I believe that a share price of $90 to 100 per share next week could be expected.

Good luck and GOD bless,

[jazz5201]

$70-80 range if not higher.

[Rensenbrink]

curious about your price target for next week?

[georgejjl]

Watch the share price and trading volume for AXSM stock INCREASE just before the close of trading TODAY!!!

Good luck and GOD bless,

[someconcerns]

Actually a good move to sell half/keep half. I did likewise, have more than my cost back in the (now free) shares I kept. I've been burned enough times by being greedy.

[Investor2014]

Good move imo.

Still some while to prove revenue potential and likely opportunity to buy in cheaper later if that seems to make sense.

[Nelson2]

I appreciate what you’re saying mate
But I have been a victim too many times where I left my Hog’s head at the trough
I have half of my position left. Let her run baby!
Hey, I could be wrong. But plenty of coin in my pocket to drown the sorrows should she run

GLTU

[Max77]

Nelson. Today is the day to buy not sell. Going much higher. Breaking all major resistance

[Nelson2]

Sold half my position. Hope your right so can sell the other half

GLTU

[georgejjl]

A MUST WATCH

https://event.choruscall.com/mediaframe/webcast.html?webcastid=0E8qLA5v

https://axsometherapeuticsinc.gcs-web.com/static-files/c43e73fb-f3d7-4f3d-b614-d18143abe31c

Good luck and GOD bless,

[georgejjl]

SHORT SQUEEZE POSSIBLE THIS AFTERNOON AND MONDAY 22 AUGUST 2022

Good luck and GOD bless,

[Frankestin]

Oh Yes
Thanks!
I’ll sell at $ 77

[Max77]

I mean !!

[Max77]

Great call! ??

[georgejjl]

This coming Monday 22 August 2022 will be one year since the FDA had planned on making a decision regarding AXS-05 for treating MDD

"...The FDA had set Sunday, Aug. 22, as its PDUFA date to approve or reject AXS-05..."


From this months resent quarterly update:

"...With regards to our NDA for AXS-05 in major depressive disorder, or MDD, we announced that we have entered into labeling discussions with the FDA in late June. We have been pleased with the progress of these discussions. And based on the interactions, we anticipate potential FDA action on the NDA in the third quarter and potentially as early as this month...."

Good luck and GOD bless,

[georgejjl]

Should you buy this week BEFORE THE NEWS???

Good luck and GOD bless,

[georgejjl]

I bought hundreds of shares if AXSM stock again today, Wednesday 17 Aug 2022.

Now is time for FDA approval of AXS-05 for treating MDD.

Good luck and GOD bless,

[georgejjl]

ANTICIPATION OF AXSM NEWS NEXT WEEK!!!

Good luck and GOD bless,

[Frankestin]

added a little!

[someconcerns]

Print Format
Change Text Size:

Default text sizeA Larger text sizeA Largest text sizeA

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
BY GlobeNewswire
— 7:00 AM ET 07/28/2022

Axsome to host conference call and webcast on Tuesday, August 9, 2022 at 8:00 AM Eastern Time

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM) , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter of 2022 on Tuesday, August 9, 2022 before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 AM Eastern Time on August 9, 2022 to discuss these results and provide a business update.

To participate in the live conference call, please dial [phone] (toll-free domestic). A live webcast of the conference call can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com. A recording of the conference call will be available on the Company’s website for approximately 30 days following the live event.

[too simple]

Adam mentioned on Fox bus today . I did not catch the name of the guy but he thinks it is good candidate for a Big Pharma purchase .

[Frankestin]

In my opinion someone here stops dancing soon, the music has changed but someone don't hear!
cover yourself before it's too expensive

[someconcerns]

AXSM filing:

http://archive.fast-edgar.com/20220721/AJ2GCG22ZC228ZA2222L2Z42BUBDZK22V242/

[Frankestin]

https://fintel.io/so/us/axsm/morgan-stanley
who despises buys

[Frankestin]

https://www.marketbeat.com/stocks/NASDAQ/AXSM/price-target/

[rosemountbomber]

Was Morgan Stanley at 27 before the upgrade to 54?

[Frankestin]

https://www.streetinsider.com/Analyst+PT+Change/Axsome+Therapeutics+%28AXSM%29+PT+Raised+to+%2454+at+Morgan+Stanley/20304472.html
Morgan Stanley Upgrade to 54
they were the lowest ones

[Frankestin]

Axsome is also working with the FDA to resolve chemistry, manufacturing, and controls issues with its regulatory submission for approval of AXS-07 in treating migraine. The company believes the issues are addressable and anticipates "an expeditious resubmission" of the New Drug Application.
Will it happen before AXS-05 is approved or after?
In my opinion first!

[georgejjl]

Axsome Therapeutics
Only a few days ago, Axsome Therapeutics (AXSM 6.11%) stock was down more than 50% year to date. However, its shares skyrocketed last week after the company revealed that the U.S. Food and Drug Administration (FDA) has proposed labeling for experimental drug AXS-05 in treating major depressive disorder (MDD).

This is an important step toward Axsome potentially winning FDA approval for AXS-05 in the MDD indication. Axsome is also evaluating the drug in a late-stage study for treating Alzheimer's disease agitation. Analysts think the drug could generate peak sales of more than $1 billion if approved.

Axsome is also working with the FDA to resolve chemistry, manufacturing, and controls issues with its regulatory submission for approval of AXS-07 in treating migraine. The company believes the issues are addressable and anticipates "an expeditious resubmission" of the New Drug Application.

In addition, Axsome is acquiring sleep-disorder drug Sunosi from Jazz Pharmaceuticals. Sales for the drug more than doubled in 2021 to $57.9 million.

All of this potentially good news makes Axsome's current market cap of around $1.5 billion look very cheap. This stock appears to have a good chance of delivering strong gains in the second half of 2022.

Good luck and GOD bless,

[Frankestin]

https://www.nasdaq.com/articles/got-%24500-3-absurdly-cheap-healthcare-stocks-that-are-set-to-skyrocket

https://fintel.io/sst/us/axsm
Lots of sales on Friday! many S and few M.

Put some cash here for your retirement
https://fintel.io/so/us/axsm

[Investor2014]

I agree with you, the immediate future of the $AXSM stock price is already baked in.

Only back in 2019 the stock was much higher on irrational over exuberance.

Watch out for the persistent pumping.

[rosemountbomber]

All well and good, but what is the market penetration and insurance coverage?

Notice that there are a couple of other meds that are much cheaper so is Sunosi making any inroads?

https://www.goodrx.com/wake-promoting-agents

Think if we get the company to pr that they are accepting the FDA labeling request for AXS-05 the stock bumps up some more, but I worry that upon FDA approval announcement that profit taking sets in. This should be higher as the labeling discussion basically means the drug is approved so I think it is pretty much baked in.

Any significant drop in stock price after approval would be a great buying opportunity as over the next 18 months as sales start coming in, valuations would rise.

[Frankestin]

https://www.fool.com/investing/2022/06/30/2-biotechs-that-recently-soared-are-they-buys/

[Frankestin]

If I were someone who ran short I would hope for a dilution ..
Even assuming they will do a capital increase in your opinion when they do: before or after declaration of approval?
Cover before it's too late!
https://fintel.io/sst/us/axsm

[Frankestin]

reminds me of somaxon pharma somx ...
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022036s000ltr.pdf

[Frankestin]

https://www.marketbeat.com/stocks/NASDAQ/AXSM/price-target/?RegistrationCode=SocialMedia-StockTwits&utm_source=GeneralSocialMedia&utm_medium=Social&utm_campaign=SocialMedia
Cowen 120 to 130

[Frankestin]

Brokerage believes Sunosi has potential to become a mainstay as first-line non-generic therapeutic in these indications; assumes peak market penetration of 14%
Cantor Fitzgerald raises PT for drug developer Axsome Therapeutics (AXSM.O) to $64 from $47 on growth potential of its newly acquired drug Sunosi

[Frankestin]

STRONG BUY
https://fintel.io/sst/us/axsm
from next week approval at any time!

[georgejjl]

Current trial in progress

Solriamfetol for ADHD in Adults: A Double-Blind Placebo Controlled Pilot Study
Actual Study Start Date : August 6, 2021
Estimated Primary Completion Date : January 1, 2023
Estimated Study Completion Date : May 1, 2023

https://clinicaltrials.gov/ct2/show/NCT04839562

Good luck and GOD bless,

[georgejjl]

Sanosi cost per person per month

$755 for a 30 day supply for the WAC (Wholesaler Acquisition Cost) which a gross margin that is expected to be in the high 70%'s.

Good luck and GOD bless,

[Frankestin]

https://axsometherapeuticsinc.gcs-web.com/static-files/560e430e-0f21-4514-90b9-a34330b6e524

[Frankestin]

FDA proposed labeling for depression drug
Do you have doubts that it will be approved?
Those who sell do not understand what it means!

[Frankestin]

$ 200
cover up soon or it will be bitter cocks!